Covid-19 roundup: AlloVir snags IND ap­proval for po­ten­tial T cell ther­a­py; Sanofi and GSK strike 300 mil­lion-dose deal with the EU 

Af­ter snag­ging IND ap­proval for its off-the-shelf virus-spe­cif­ic T cell Covid-19 ther­a­py, AlloVir is now rac­ing to­ward a proof-of-con­cept study.

The can­di­date, ALVR109,  is de­signed to halt the pro­gres­sion of Covid-19 by de­stroy­ing SARS-CoV-2-in­fect­ed cells.

In March, AlloVir ex­pand­ed its part­ner­ship with the Bay­lor Col­lege of Med­i­cine to de­vel­op treat­ments that re­store T-cell im­mu­ni­ty in im­mune-com­pro­mised pa­tients. In ad­di­tion to Covid-19, the pro­gram pur­sues SARS clas­sic, MERS and four oth­er coro­n­avirus­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER